CytomX Therapeutics, Inc. (CTMX) — Financial statements
Income statement, balance sheet, and cash flow for CytomX Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 76↓44.8% | 138↑36.4% | 101↑90.4% | 53↑42.5% | 37 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 76↓44.8% | 138↑36.4% | 101↑90.4% | 53↑42.5% | 37 | |
| Operating Expenses | ||||||
| R&D Expenses | 69↓17.6% | 83↑7.3% | 78↓30.4% | 112↓2.2% | 114 | |
| General & Administrative Expenses | 30↑0.4% | 30↓1.0% | 30↓29.9% | 43↑9.4% | 39 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 30↑0.4% | 30↓1.0% | 30↓29.9% | 43↑9.4% | 39 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 99↓12.9% | 113↑5.0% | 108↓30.3% | 154↑0.7% | 153 | |
| Total Costs & Expenses | 99↓12.9% | 113↑5.0% | 108↓30.3% | 154↑0.7% | 153 | |
| Operating Results | ||||||
| Operating Income | -22↓189.5% | 25↑485.5% | -6↑93.6% | -101↑12.7% | -116 | |
| Depreciation & Amortization | 1↓22.2% | 2↓18.7% | 2↓11.0% | 2↓9.7% | 3 | |
| EBITDA | -21↓178.4% | 27↑721.1% | -4↑95.6% | -99↑12.7% | -113 | |
| EBIT | -22↓189.5% | 25↑485.5% | -6↑93.6% | -101↑12.7% | -116 | |
| Interest & Other Income | ||||||
| Net Interest Income | 5↓27.0% | 7↓27.5% | 10↑486.2% | 2↑558.0% | 0.26 | |
| Interest Income | 5↓27.0% | 7↓27.5% | 10↑486.2% | 2↑558.0% | 0.26 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 5↓26.3% | 7↓27.6% | 10↑386.0% | 2↑1073.3% | 0.17 | |
| Income Before Tax | -17↓153.4% | 32↑865.8% | 3↑103.3% | -99↑14.3% | -116 | |
| Income Tax Expense | 0.24↑6.3% | 0.22↓94.2% | 4 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -17↓154.5% | 32↑5700.9% | -0.57↑99.4% | -99↑14.3% | -116 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -17↓154.5% | 32↑5700.9% | -0.57↑99.4% | -99↑14.3% | -116 | |
| Bottom-Line Net Income | -17↓154.5% | 32↑5700.9% | -0.57↑99.4% | -99↑14.3% | -116 | |
| EPS (Basic) | -0.15↓139.5% | 0.38↑5035.1% | -0.01↑99.5% | -1.48↓17.5% | -1.26 | |
| EPS (Diluted) | -0.15↓139.5% | 0.38↑5035.1% | -0.01↑99.5% | -1.48↓17.5% | -1.26 | |
| Weighted Average Shares | 138↑63.4% | 84↑14.4% | 74↑12.3% | 66↑2.5% | 64 | |
| Weighted Average Diluted Shares | 138↑62.8% | 85↑14.8% | 74↑12.3% | 66↑2.5% | 64 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.